ArticlePharmaceuticals (Basel, Switzerland)2023
Purification Effect of PES-C Ultrafiltration Membrane Incorporated with Emodin on Acanthopanax Senticosus Injection.
Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
A new PES-C/emodin ultrafiltration membrane was prepared by blending natural emodin with phenolphthalein polyethersulfone (PES-C) and was used to purify an acanthopanax senticosus injection in this study. Regarding the purified acanthopanax senticosus injection, its color became lighter, and its clarity increased. On the contrary, for an acanthopanax senticosus injection containing macromolecules, its color deepened, and its turbidity increased. Thermal stability of the purified acanthopanax senticosus injection was the best, followed by the original solution of the acanthopanax senticosus injection, and the acanthopanax senticosus injection containing macromolecules was the worst. The fingerprint spectrum of the purified acanthopanax senticosus injection was similar to the original solution of the acanthopanax senticosus injection, the relative peak area of each single peak was greater than 0.95, and the relative peak area of the total peak was greater than 0.96. Compared with the original solution of the acanthopanax senticosus injection, the histamine release amount and cell degranulation rate of the acanthopanax senticosus injection containing macromolecules increased, while those of the purified acanthopanax senticosus injection decreased, which reduced the risk of allergic reaction to a certain extent. "Inverse proof" confirmed that the acanthopanax senticosus injection containing macromolecules had certain liver and kidney toxicity, which indirectly proved that the liver and kidney toxicity of the purified acanthopanax senticosus injection was effectively reduced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.